Evit Labs announces collaboration with NovaCal Pharmaceuticals to combat bio-terrorism

EVIT Labs, Inc. today announced the signing of a letter of intent with NovaCal Pharmaceuticals, LLC of Novato, California for the development of NovaCal's NVC101 as an inhaled antimicrobial agent delivered to the lung by the Sonik LDI (liquid dispensing inhaler) for possible use against certain pulmonary infections.

IMMEDIATE RELEASE

Evit Labs announces collaboration with NovaCal Pharmaceuticals to combat bio-terrorism

McCLELLAN, Calif., Feb 27, 2002 - EVIT Labs, Inc. today announced the signing of a letter of intent with NovaCal Pharmaceuticals, LLC of Novato, California for the development of NovaCal's NVC101 as an inhaled antimicrobial agent delivered to the lung by the Sonik LDI (liquid dispensing inhaler) for possible use against certain pulmonary infections. As a sign of times, EVIT and NovaCal are particularly interested in developing NVC101 for the treatment of inhalation Anthrax. Lawrence Berkeley National Laboratory, in Berkeley CA, has agreed to perform initial screening of NVC101 against Anthrax. Other potential uses of NVC101 for pulmonary applications are being explored through the joint efforts of NovaCal and EVIT.

About the Company

Founded in 2000, Evit Labs, Inc., is the leader in sonic delivery of high quality aerosol pharmaceutical, proteins and peptides through its patented Sonik LDI (liquid dispensing inhaler. The company offers drug and biotech companies a unique platform in which to deliver treatment to the lungs.

NovaCal Pharmaceuticals, LLC is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of patented therapeutic products for the control or elimination of infections. Currently, NovaCal is focused on clinical development and regulatory approval of NVC101 as a unique anti-microbial product.

NOTE: Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements and involve risks and uncertainties. They include our reliance on our collaborative partners and our ability to properly design, implement and complete clinical trial; meet regulatory requirements; demonstrate safety and efficacy of products; manage third-party contracts; and avoid infringement of third-party proprietary rights. Actual results may differ materially from those projected. These forward-looking statements represent our best judgment as of the date of the release. We disclaim any intent or obligation to update these forward-looking statements.

Contact Information:

Jon Bergstrom, EVP
Evit Labs
916-640-0485
jberg@evitlabs.com
or
Jack O'Reilly, CEO
NovaCal Pharmaceuticals
415-883-2600
joreilly@novacalpharma.com